OTCM
ZTEKF
Market cap51mUSD
Oct 19, Last price
0.41USD
1D
-8.10%
1Q
-20.11%
Jan 2017
-35.97%
IPO
26.46%
Name
Zentek Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zentek Ltd. is a Canadian company focused on the exploration and advancement of graphene and related nanomaterials. It fully owns the Albany Graphite project, situated in Northern Ontario, Canada. The firm develops its ZenGUARD brand, a graphene-based antimicrobial coating, incorporating it into products like surgical masks, HVAC filters, and personal protective equipment. Additionally, Zentek's innovation extends to rapid detection point-of-care diagnostics and pharmaceutical products, all leveraging graphene-based compounds. The company also specializes in synthesizing graphene, graphene oxide, and graphene quantum dots for diverse applications. Founded in 2008 and headquartered in Thunder Bay, Canada, Zentek Ltd. was formerly known as ZEN Graphene Solutions Ltd. until its name change in October 2021.
Key people
Eric Wallman
Non-Executive Chairman of the Board · since 2024
Mohammed Jiwan
Chief Executive Officer, Director · since 2025
Wendy Ford
Chief Financial Officer · since 2025
Wendy Ford
Chief Financial Officer · since 2025
Ryan Shacklock
Senior Vice President - Strategy and Business Development · since 2023
Peter Wood
Vice President - Development (AGC) · since 2024
Francis Dube
Director · since 2024
Gregory Fenton
Chief Executive Officer, Director · since 2020
Lisa Sim
Independent Director · since 2023
Independent Director, Company Secretary · since 2025
Legal address
210–1205 Amber Drive
Thunder Bay, BC P7B 6M4
CA
Thunder Bay, BC P7B 6M4
CA
Headquarters
210–1205 Amber Drive
Thunder Bay, BC
CA
Thunder Bay, BC
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||